



Women's Health Innovation Series

REPRODUCTIVE HEALTH INNOVATION SUMMIT

INNOVATION SHOWCASE FINALISTS

📅 15-16 FEBRUARY, 2023

📍 BOSTON PARK PLAZA, BOSTON

The Innovation Showcase provides start-ups with innovative technologies, platforms, and devices the opportunity to present in front of our audience of over 300 leaders and potential partners. Our 2023 RHIS Finalists are:

AIBYSTM
Select with care


FutureFertility

OOVA

Nodal


nesle

proof

 **May Health**



 **MATRUBIALS**

Mae.

CurioTM

Raydiant
Oximetry 

WITH THANKS TO OUR PARTNERS

Headline Partner:

FERRING
PHARMACEUTICALS

Innovation Partner:

 **ORGANON**
Here for her health

Platinum Partner:

**EMD
SERONO**

Gold Partners:

 **GranataBio**
 **PRIA**

Event Partner:

 **AIVF**
 **Presagen**
A.I. Enhanced Healthcare

A SPECIAL THANK YOU TO THE SELECTION COMMITTEE



Maria Velissaris
Founding Partner
SteelSky Ventures



Annie Theriault
Managing Partner
Cross Border Impact
Ventures



Elizabeth Bailey
Managing Director
Rhia Ventures



Arianna Kidder
Principal and Chief
Financial Officer
Seae Ventures



Haley Gahan
Principal
Recharge Capital



Linda Greub
Managing Partner
Avestria Ventures



Margaret Malone
HealthTech Investor
Flare Capital



Jessica Karr
General Partner
Coyote Ventures



Trish Costello
Founder & CEO
Portfolia



Anula Jayasuriya
Founder & Managing Partner
ExxClaim Capital



Shalini Sardana
Co-founder & Investment
Strategist
She Raises Capital



Carli Sapir
Founding Partner
Amboy Street Ventures



INVESTOR FORUM


Investors are an integral part of the women's health ecosystem. Responsible for propelling investments, they play a critical role within the acceleration of innovation.

The Investor Forum will offer further networking and discussion for investors in the women's health space who share the same passion for driving change and accelerating innovation.

Register your interest in the forum and a team member will be in touch with further information.

REGISTER YOUR INTEREST

AND A THANK YOU TO OUR PRIZE PARTNERS...



INNNOVATION SHOWCASE FINALISTS



BAIBYS FERTILITY

<https://www.baibys.com/>

BAIBYS™ develops an autonomous system for sperm selection at high-magnification ($\times 6,100$) based on machine-vision, AI, and micro-robotics. The system shall be used in ART laboratories for automatically and objectively selecting the optimal spermatozoa for ICSI (including the physical pick-up and relocation into target droplets) according to accepted morphology and motility criteria in a fraction of the time and cost of the current manual process. The system is comprised of a reusable console and disposable cartridges, in which the processed sperm sample is placed at the beginning of the process. A few minutes after pressing the start button, the cartridge is ejected with the optimal spermatozoa in designated droplets, ready for ICSI. The system shall raise IVF success rates, reduce the economic burden on health systems, raise clinics' throughput, make IVF more accessible globally, and most importantly, reduce birth defects and help more families in having healthy BAIBYS™.



Yaron Silberman
CEO
BAIBYS Fertility

Dr. Yaron Silberman is the CEO of BAIBYS™ Fertility, an early-stage start-up in the field of Assisted Reproductive Technology. Yaron brings over 25 years of executive management in international medical device companies. Prior to BAIBYS™, Yaron held a CEO position at ScoutCam, a public, 40-employee global leader in micro visualization, and led it to a strategic deal with J&J. Yaron held various business and commercial roles at Siemens Healthcare, Given Imaging (sold to Medtronic in \$1B), and other Israeli innovative start-ups. Yaron holds a PhD from the Hebrew University of Jerusalem, EMBA from the Israeli College of Management (magna cum laude), and BSc in Theoretical Mathematics from the Technion - Israeli Institute of Technology (magna cum laude).

INNNOVATION SHOWCASE FINALISTS



FutureFertility

FUTURE FERTILITY

<https://futurefertility.com/en/>

Future Fertility is an early-stage AI company - based in Toronto with a global footprint. We have developed a non-invasive, clinically validated AI-based tool that assesses 2D oocyte images to predict the likelihood of becoming a usable blastocyst. We are the first company globally to create a standard of care for assessing egg quality, revolutionizing the practice of fertility globally. Our AI tool delivers a drastic improvement upon the current standard of care for oocyte assessment (which is a manual assessment by embryologists), providing access to improved, personalized information to guide fertility decisions. The ability to provide objective egg assessments has significant downstream effects on patient outcomes and success rates due to better information, better patient counselling/expectations setting, and more consistent objective assessments of eggs in the lab.



Christy Prada
CEO
Future Fertility

Christy is the CEO at Future Fertility, a Toronto based AI company focused on closing critical information gaps in the fertility journey. She has a track record as a builder, spending her career creating and guiding high-performing teams across a range of fields, including developing and scaling new models for commercial growth at start-ups. Prior to Future Fertility, Christy was the VP Business Development at Maple, Canada's leading virtual care provider. Joining as the third employee, Christy spent over 4 years scaling the team and commercial business, creating and leading the go-to-market strategy and execution for the B2B business. Christy is also an investor as a limited partner with the Women's Equity Lab, Toronto Chapter, investing in early stage women-led ventures. With this experience combined with her passion for finding innovative solutions to the world's toughest healthcare challenges, Christy leads the Future Fertility team in its mission to empower fertility doctors, specialists, and patients with advanced AI-driven insights globally.

INNNOVATION SHOWCASE FINALISTS

Mae.

MAE

<https://meetmae.com/>

Maternal health in the U.S. is hugely inequitable, with Black mothers disproportionately experiencing poor outcomes. Mae is a digital health platform offering complete, continuous, culturally resonant digital pregnancy support combined with an on-the-ground community doula-led model of care to redefine the pregnancy experience for our most underserved. Through risk assessment and early symptom awareness, health literacy, lifestyle content, and a culturally competent network of pregnancy experts, Mae provides access to preventative care, while also bolstering physical and emotional support for Black expectant mothers.

Mae works in partnership with payer partners to improve outcomes and quality of life for plan members, reduce avoidable clinical costs, and deliver impactful pregnancy support at scale. A life of good health begins in the womb, and we can help to deliver it together, for every mother.



Maya Hardigan
CEO & FOUNDER
Mae

Maya Hardigan is the founder and CEO of Mae: a culturally responsive digital first platform connecting Black expectant and new mothers with critical resources to drive positive pregnancy outcomes. Prior to founding Mae, Maya spent 15 years in digital healthcare, most recently at Pfizer, with a primary focus on building and scaling technologies to engage, inform, and optimize care for patients, while also driving financial and operational efficiencies for healthcare payers. Maya holds a Bachelors in Biology and Psychology from Duke University and a MBA from Columbia Business School. She is the proud mama of three little girls, and resides in Brooklyn, NY.

INNOVATION SHOWCASE FINALISTS



OOVA

<https://oova.life/>

Oova is the fertility translator that fully illuminates a woman's fertility, giving her and her care team the clearest steps to conception. Founded by doctors and backed by Mount Sinai Hospital, Oova has created a consumer-first, data-driven experience valuable to both patients and healthcare providers. Oova's at-home urine test measures both luteinizing hormone and progesterone to immediately inform a woman of her most fertile days and confirm ovulation. By delivering advanced personalized analytics and real-time action plans with every hormone reading, Oova is transforming the fertility care experience.



Amy Divaraniya
MD, CEO & Founder
Oova

Dr. Amy Divaraniya is the Founder and CEO of Oova, a women's health company. She has more than 10 years of experience as a data scientist and has both led and published original research in the areas of personal genomics and biomarker discovery. Dr. Divaraniya's PhD work involved building and analyzing molecular networks to evaluate key drivers and overlapping biological processes in inflammatory diseases. Her solid understanding of biology and being able to apply complex analyses have led to innovative projects in the healthcare space. In 2017, Dr. Divaraniya chose to pivot her career as a data scientist and devote herself to improving women's healthcare. After facing her own struggles with conceiving her son, Dr. Divaraniya decided to build a solution to help women experiencing difficulty getting pregnant. Today, she and her team have built the first at-home test, Oova, that measures multiple hormones through urine samples and provides personalized results and insights on a woman's fertility. Oova has resonated with many women and clinicians and has now been adopted by over 100 clinics and hospitals across the country.

INNNOVATION SHOWCASE FINALISTS



NESSLE

<https://www.nessle.com/>

Nessle is a parent-support marketplace where parents find—and get found by—their ideal expert throughout the journey of parenthood. Our online platform provides the tools necessary for parenting experts to grow their consulting businesses, and our subscription offering makes it easy and affordable for businesses, health systems, and municipalities to uplift the parents in their orbit with full-spectrum concierge support.



Carly Buxton
PhD, CEO & Co-Founder
Nessle

Carly Buxton, PhD is Co-Founder and CEO of Nessle, a parent-support marketplace that's changing the way parents get evidence-based guidance online. Carly is a Certified Lactation Counselor and Postpartum Doula with a background in user experience research and product management. She's also a historian with a passion for bringing empathy to historical practice and experience design.

INNNOVATION SHOWCASE FINALISTS

Nodal

NODAL

<https://www.nodal.com/>

The path to parenthood isn't always a straight line. For many couples and individuals, surrogacy — a process that typically costs north of \$100,000 per child — is their best option for growing their family. The slow-moving and antiquated process can take years, complete with hidden costs and unforeseeable issues that can make the experience incredibly stressful, sometimes heartbreaking and often unattainable. Enter Nodal.

Nodal is a surrogacy x intended parent matching platform that empowers the surrogate to make the first move, offering transparency, equity, education, and support for all parties on their journey. Founded by Dr. Brian Levine, Nodal's goal is to make surrogacy an attainable option for more intended parents and to give surrogates an exceptional, empowered experience.



Brian Levine
M.D., CEO & Founder
Nodal

Dr. Brian Levine is the CEO and founder of Nodal, a surrogacy matching platform that offers transparency, equity, education and support to both surrogates and intended parents. Before founding Nodal, Dr. Levine started one of New York City's most recognized fertility practices.

Considered one of the world's foremost experts on IVF and surrogacy, Dr. Levine is board-certified in both reproductive endocrinology and infertility and obstetrics and gynecology. In 2015, Dr. Levine was awarded the highest prize by the American Society of Reproductive Medicine. He has been named by his peers as one of New York's "Top Doctors" for years.

Dr. Levine attended New York University School of Medicine and served as the president of the NYU Alumni Association. He completed his residency and fellowship at NewYork-Presbyterian Hospital Columbia and Cornell (respectively). He resides in New York City with his wife and two daughters, Izabel and Adison.

INNOVATION SHOWCASE FINALISTS

CurioTM

CURIO

[https://www.curiodigitaltx.com/.](https://www.curiodigitaltx.com/)

Curio provides comprehensive health care solutions for women throughout the cycle of life. We focus on delivering proven digital behavioral health interventions combined with connectivity to healthcare providers, digital health coaches, and resources. Our programs are developed to give women high-quality care that is targeted for each situation.



Shailja Dixit
MD, MS, MPH, CEO
Curio Digital Therapeutics

Dr. Dixit is a Physician Executive with more than 20 years of experience in the healthcare and life sciences industry. She has been in executive leadership at Sanofi, Allergan, and GE and has been responsible for launching a number of innovative medicines. She was voted innovator of the year at GE in 2008, nominated as a Top 50 Thought Leader in “Big Data” in Life Sciences in 2016, and featured in the Pharma Executive Magazine cover-page article “Real-World Evidence: From Volume to Value” (Oct 13, 2016). Shailja has built and has had successful exits with many projects.

INNNOVATION SHOWCASE FINALISTS



MAY HEALTH

<https://www.mayhealth.com/>

May Health is a clinical stage medical device company developing a breakthrough treatment to restore ovulation for PCOS-related infertility. Poly Cystic Ovarian Syndrome (PCOS) affects over 10% of women worldwide and causes hormone imbalances that result in reproductive, metabolic, and endocrine symptoms, and it is the #1 cause of infertility. The company is currently conducting feasibility studies in Europe and the United States and will be conducting future clinical studies to support a PMA application as well as CE mark.



Anne Ballinger Morrissey
CEO
May Health

Anne Ballinger Morrissey currently serves as the Chief Executive Officer of May Health. Anne, is a veteran of the life sciences industry with over 20 years across medical devices, diagnostics and biotech. Anne is a successful and passionate leader with a specific focus on women's health.

Anne was Chair and CEO of Alydia Health which was acquired by Organon/Merck for \$240M in 2021 (Fierce Medtech's 2021 Fierce 15). Anne transformed this struggling, early-stage startup into a commercially ready, scalable medical device company addressing the number one cause of maternal mortality: postpartum hemorrhage. Under her leadership, Alydia raised \$23M, built an outstanding team and completed a Pivotal Trial which led to 510K clearance and commercialization of the Jada System. Prior to Alydia, Anne held leadership roles in marketing and business development at GSI (TYCO) and co-founded Vivant Medical (TYCO). She has been instrumental in building companies that have collectively exited for \$400M+. Her early career includes sales roles at Kimberly-Clark Corporation (NYSE: KMB) and Mentor.

Previously, as the Vice President at Astia, an organization dedicated to accessing venture capital for female founders, Anne worked with entrepreneurs and investors, managing a portfolio of early-stage, primarily Series A, companies across Life Science, Tech, Cleantech, and Consumer. Today, Astia has grown from an accelerator, to include an angel investor group, and recently closed a \$100M fund, where Anne is an advisor and limited partner.

Anne currently serves on the board of directors of Femasys (Nasdaq:FEMY), serving on their audit, and nominating and governance committee. Anne is also a board director for Ark Surgical.

Anne holds a B.A. in History from Willamette University.

INNOVATION SHOWCASE FINALISTS

proof

PROOV

<https://proovtest.com/>

Proov is a platform that screens for up to 87% of the common causes of infertility non-invasively and at home. Our fertility test kits are FDA-cleared, CE marked, clinically validated and patented. If Proov flags a potential issue, we offer cycle support products and access to fertility care via telehealth. A recent clinical study shows that positive Proov results can increase pregnancy chances by 8X.



Amy Beckley
PhD, CEO & Founder
Proov

Amy Beckley has a PhD in Pharmacology and has been studying hormone signaling for over 20 years. Her passion for reproductive hormone signaling occurred after she had a personal battle with infertility and recurrent miscarriage. No test or doctor could explain her losses so she ultimately turned to IVF to have her son. It was only after she uncovered the source of her troubles — a problem with ovulation — that she successfully conceived, this time only needing a simple, inexpensive medication. She then set out to create an accurate, effective diagnostic to empower women to test at home.

INNNOVATION SHOWCASE FINALISTS



IMMA HEALTH

<https://www.imma.health/>

Founded in 2021 by a team of physicians, engineers, and business experts, IMMA health, is a privately held women-led, Israel-based medtech women's health startup, focused on building the best comprehensive solution for transvaginal scans (TVS) from home, with remote medical monitoring service, in patient autonomy. Winner of 24h TelAviv Bootcamp 2020 and MassChallenge 2021 Israel competition. In 2022, IMMA was part of Mc Kinsey Cohort Women entrepreneur, Israel Yazamiyot-Microsoft cohort, and Tech4Eva accelerator.

We create a secure and accurate system for women to perform their own transvaginal ultrasound scans for themselves, in the comfort, safety and intimacy of their home.

IMMA is scalable into a tech platform for Women's Health that can be used all along women's life for many other indications (no-touch pelvic exam, natural fertility, hormone-free contraception, cervix length monitoring, endometriosis, PCOS, cancer screening and so on). Putting together a unique longitudinal ultrasound dataset throughout woman's different life stages, from puberty, contraception to menopause and helping to bridge the gender data gap and leading to new Bio-Markers development.

Her health in her hands, quite literally.



Nadia Prisant MD, MSc, MBA, Co-Founder & Chief Medical Officer IMMA Health

Dr Nadia Prisant is a French MD, specialized in Laboratory Fertility Medicine. After studying medicine at Paris V, completing a residency at the Lyon I-Claude Bernard Faculty and a Fertility Medicine Fellowship at the Pitie Salpetriere Hospital in Paris, she was Lab Director at Laboratoire d'Eylau, Clinique de la Muette, before joining the team of the only public IVF Laboratory in the French Caribbean.

She holds 2 master's degrees in Infertility Medicine and Research as well as Degrees in Medical Hypnosis, Sexual Therapy and Andrology and an MBA from Reichman University in Israel. Former General Secretary of the SALF (Societe d'Andrologie de Langue Française) and a member of several Medical Societies, she has published medical papers in peer reviewed medical journals, and spoken at medical conferences around the world, notably on the emergence of the Zika virus epidemic in the Caribbean and its impact on human fertility.

Cofounder and Chief Medical Officer of IMMA health, an Israeli Femtech venture, creating a comprehensive solution for transvaginal scans from home, in non-expert hands.

INNNOVATION SHOWCASE FINALISTS



MATRUBIALS
<https://matrubials.com/>

Matrubials Inc. is developing milk-inspired therapeutics to address infectious diseases. Globally, drug-resistant infections cause ~1.2M deaths a year. In women, recurrent bacterial vaginosis and subsequent repeat urinary tract and yeast infections and reproductive issues remain unresolved for ~1bn women world-wide. This is because existing antibiotics are either resistant to in ~68% patients, or are non-selective and alter the healthy microbiome. Milk-inspired patent-pending antimicrobial peptide(s) in Matrubials' portfolio can be scaled in a lab and developed into topical applications to reduce this burden (FDA route- medical product), and additional infections, starting with skin & soft tissue infections (B2B/DTC route- cosmetic product), impacting all genders using an AI-enabled platform for candidate expansion.



Ishita M. Shah
PhD, CEO & Co-Founder
Matrubials

Ishita M. Shah, PhD, is the CEO and co-founder of Matrubials, a spin-out from UC Davis, Foods for Health Institute. As the Associate Director (Microbial Programs) at FFHI, she has investigated the role of milk components in human health, specifically in terms of infectious diseases, that led to founding Matrubials. Previously, Dr. Shah has worked at Genentech (Senior researcher, infectious diseases) and Columbia University (Postdoctoral scientist), receiving several awards (PhD thesis prize - (UMBC'05), Nat Sternberg most outstanding thesis award/ key researcher- Genetech/ best speaker of the year- IMGCC).

INNNOVATION SHOWCASE FINALISTS



RAYDIANT OXIMETRY

<https://www.raydiantoximetry.com/>

Raydiant Oximetry, Inc is a medical device company dedicated to improving outcomes for mothers and babies during childbirth with the Lumerah™ platform by addressing emergency C-sections, newborn birth injury and postpartum hemorrhage. Lumerah received breakthrough device status from the FDA for expedited market clearance and is currently in clinical stage of development.



Neil P. Ray
MD, CEO & Founder
Raydiant Oximetry

Neil P. Ray, MD is the CEO and founder of Raydiant Oximetry. He is a board-certified pediatric anesthesiologist and nominated for physician-entrepreneur of the year by the Society of Physician Entrepreneurs (SoPE) in 2021.



Women's Health Innovation Series

REPRODUCTIVE HEALTH INNOVATION SUMMIT



PRICING

PASS TYPE	Standard
ACADEMIC/NPO/CHARITY	\$699
EMERGING - UNDER 5MIL	\$999
EMERGING - UNDER 10MIL	\$1,199
INDUSTRY	\$2,099
SERVICE PROVIDERS	\$2,899

JOIN THE FINALISTS

REGISTER TODAY

Headline Partner:



Innovation Partner:



Platinum Partner:



Gold Partners:



Event Partner:

